Cargando…

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society

Recent advances in human genetics, together with a large body of epidemiologic, preclinical, and clinical trial results, provide strong support for a causal association between triglycerides (TG), TG-rich lipoproteins (TRL), and TRL remnants, and increased risk of myocardial infarction, ischaemic st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ginsberg, Henry N, Packard, Chris J, Chapman, M John, Borén, Jan, Aguilar-Salinas, Carlos A, Averna, Maurizio, Ference, Brian A, Gaudet, Daniel, Hegele, Robert A, Kersten, Sander, Lewis, Gary F, Lichtenstein, Alice H, Moulin, Philippe, Nordestgaard, Børge G, Remaley, Alan T, Staels, Bart, Stroes, Erik S G, Taskinen, Marja-Riitta, Tokgözoğlu, Lale S, Tybjaerg-Hansen, Anne, Stock, Jane K, Catapano, Alberico L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Special Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670783/ https://www.ncbi.nlm.nih.gov/pubmed/34472586 http://dx.doi.org/10.1093/eurheartj/ehab551

Ejemplares similares

Lipoprotein(a) as a cardiovascular risk factor: current status
por: Nordestgaard, Børge G., et al.
Publicado: (2010)

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
por: Chapman, M. John, et al.
Publicado: (2011)

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
por: Ference, Brian A., et al.
Publicado: (2017)

Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study
por: Björnson, Elias, et al.
Publicado: (2023)

Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
por: Taskinen, Marja-Riitta, et al.
Publicado: (2019)

The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
por: Borén, Jan, et al.
Publicado: (2020)

Causes and Consequences of Hypertriglyceridemia
por: Packard, Chris J., et al.
Publicado: (2020)

Dietary Fructose and the Metabolic Syndrome
por: Taskinen, Marja-Riitta, et al.
Publicado: (2019)

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
por: Cuchel, Marina, et al.
Publicado: (2014)

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease : Consensus Statement of the European Atherosclerosis Society
por: Nordestgaard, Børge G., et al.
Publicado: (2013)

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
por: Borén, Jan, et al.
Publicado: (2020)

Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment
por: Wiegman, Albert, et al.
Publicado: (2015)

High-density lipoprotein revisited: biological functions and clinical relevance
por: von Eckardstein, Arnold, et al.
Publicado: (2022)

Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?
por: Taskinen, Marja-Riitta, et al.
Publicado: (2016)

2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance
por: Cuchel, Marina, et al.
Publicado: (2023)

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement( )
por: Kronenberg, Florian, et al.
Publicado: (2022)

Genetic Variation in SULF2 Is Associated with Postprandial Clearance of Triglyceride-Rich Remnant Particles and Triglyceride Levels in Healthy Subjects
por: Matikainen, Niina, et al.
Publicado: (2013)

Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract
por: Mach, François, et al.
Publicado: (2018)

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
por: Stroes, Erik S., et al.
Publicado: (2015)

Kinetic Studies to Elucidate Impaired Metabolism of Triglyceride-rich Lipoproteins in Humans
por: Adiels, Martin, et al.
Publicado: (2015)

Transatlantic Lipid Guideline Divergence: Same Data But Different Interpretations
por: Orringer, Carl E., et al.
Publicado: (2020)

Improved Estimation of Human Lipoprotein Kinetics with Mixed Effects Models
por: Berglund, Martin, et al.
Publicado: (2015)

Editorial: Rare dyslipidemias
por: Sadiq, Fouzia, et al.
Publicado: (2023)

Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration
por: Ference, Brian A, et al.
Publicado: (2018)

The spoils of war and the long-term spoiling of health conditions of entire nations
por: Navarese, Eliano P., et al.
Publicado: (2022)

Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapy
por: Taskinen, Marja-Riitta, et al.
Publicado: (2023)

Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease
por: Packard, Chris J.
Publicado: (2022)

Reflections from ACC 2015
por: Tokgözoğlu, Lale
Publicado: (2015)

Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single‐centre randomized controlled study
por: Matikainen, Niina, et al.
Publicado: (2018)

Twelve Variants Polygenic Score for Low‐Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations
por: Olmastroni, Elena, et al.
Publicado: (2022)

Genetic variation in clusterin and risk of dementia and ischemic vascular disease in the general population: cohort studies and meta-analyses of 362,338 individuals
por: Nordestgaard, Liv Tybjærg, et al.
Publicado: (2018)

Highlights form ESC 2015
por: Tokgözoğlu, Prof. Lale
Publicado: (2015)

Genetic variants in the adenosine triphosphate-binding cassette transporter A1 and risk of age-related macular degeneration
por: Nordestgaard, Liv Tybjærg, et al.
Publicado: (2023)

Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?
por: Dallinga-Thie, Geesje M., et al.
Publicado: (2016)

Highlights from ACC 15 Scientific Sessions: Part 1
por: Kaymaz, Cihangir, et al.
Publicado: (2015)

Highlights from ACC 15 Scientific Sessions: Part 2
por: Kaymaz, Cihangir, et al.
Publicado: (2015)

What do the “new” Pulmonary Hypertension Guidelines tell us: should we change our practice?
por: Kaymaz, Cihangir, et al.
Publicado: (2016)

Current Treatment Options in Homozygous Familial Hypercholesterolemia
por: Kayikcioglu, Meral, et al.
Publicado: (2022)

Comparison of Current International Guidelines for the Management of Dyslipidemia
por: Aygun, Sevda, et al.
Publicado: (2022)

Effect of HDL composition and particle size on the resistance of HDL to the oxidation
por: Shuhei, Nakanishi, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ep82cdu9pf6tc79c0fv6c96n9l